tokens: It was approved on 17 June 2013 by the European Medicines Agency for use in patients with low - or intermediate-1 - risk myelodysplastic syndromes who have 5q - deletion syndrome but no other cytogenetic abnormalities and are dependent on red blood cell transfusions , for whom other treatment options have been found to be insufficient or inadequate .